Business Standard

Lancet study finds no benefit for hydroxychloroquine in Covid-19 patients

The scientists said these drugs should not be used to treat Covid-19 patients outside of clinical trials until results from randomised clinical trials are available to confirm their safety

Medics collect a swab sample of an air passenger from Chicago for COVID-19 test who landed in Hyderabad and arrived at his native city by bus, during the ongoing Covid-19 nationwide lockdown, in Vijayawada. Photo: PTI
Premium

Medics collect a swab sample of an air passenger from Chicago for COVID-19 test who landed in Hyderabad and arrived at his native city by bus, during the ongoing Covid-19 nationwide lockdown, in Vijayawada. Photo: PTI

Press Trust of India New Delhi
Treatment for Covid-19 with the antimalarial drug hydroxychloroquine, either with or without the antibiotic azithromycin, offers no benefit for Covid-19 patients, according to a large observational study.

The research, published in the journal The Lancet, analysed data from nearly 15,000 patients with Covid-19 who received chloroquine or its analogue hydroxychloroquine, taken with or without the antibiotics azithromycin or clarithromycin, and 81,000 controls.

According to the researchers, including Mandeep Mehra from Brigham and Women's Hospital in the US, Covid-19 patients on these drug regimens, experienced an increased risk of serious heart rhythm complications.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 22 2020 | 9:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com